Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: Variables affecting specificity and effectiveness by Farra, Rossella et al.
molecules
Review
Polymer-Mediated Delivery of siRNAs to
Hepatocellular Carcinoma: Variables Affecting
Specificity and Effectiveness
Rossella Farra 1, Francesco Musiani 2 ID , Francesca Perrone 3, Maja Cˇemažar 4,5 ID ,
Urška Kamenšek 4 ID , Federica Tonon 3, Michela Abrami 1, Aleš Rucˇigaj 6, Mario Grassi 1 ID ,
Gabriele Pozzato 7, Deborah Bonazza 7, Fabrizio Zanconati 7, Giancarlo Forte 8 ID ,
Maguie El Boustani 9,10, Lucia Scarabel 9,11, Marica Garziera 9, Concetta Russo Spena 9,11,
Lucia De Stefano 9,11, Barbara Salis 9,10, Giuseppe Toffoli 9, Flavio Rizzolio 9,12,
Gabriele Grassi 3,7,* and Barbara Dapas 3
1 Department of Engineering and Architecture, University of Trieste, Via Alfonso Valerio, 6/A,
I-34127 Trieste, Italy; rfarra@units.it (R.F.); Michela.Abrami@dia.units.it (M.A.);
mario.grassi@dia.units.it (M.G.)
2 Laboratory of Bioinorganic Chemistry, Department of Pharmacy and Biotechnology, University of Bologna,
I-40127 Bologna, Italy; Francesco.musiani@unibo.it
3 Department of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447,
I-34149 Trieste, Italy; Francesca.Perrone@phd.units.it (F.P.); effetonon@gmail.com (F.T.);
bdapas@units.it (B.D.)
4 Department of Experimental Oncology, Institute of Oncology, Ljubljana, Zaloska 2,
SI-1000 Ljubljana, Slovenia; MCemazar@onko-i.si (M.Cˇ.); UKamensek@onko-i.si (U.K.)
5 Faculty of Health Sciences, University of Primorska, Polje 42, SI-6310 Izola, Slovenia
6 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Vecˇna pot 113,
SI-1000 Ljubljana, Slovenia; Ales.Rucigaj@fkkt.uni-lj.si
7 Department of “Scienze Mediche, Chirurgiche e della Salute”, University of Trieste, Cattinara Hospital,
Strada di Fiume 447, I-34149 Trieste, Italy; G.POZZATO@fmc.units.it (G.P.);
deborah.bonazza@asuits.sanita.fvg.it (D.B.); fabrizio.zanconati@asuits.sanita.fvg.it (F.Z.)
8 Center for Translational Medicine (CTM), International Clinical Research Center (ICRC),
St. Anne’s University Hospital, Studenstka 6, 656 91 Brno, Czech Republic; giancarlo.forte@fnusa.cz
9 Experimental and Clinical Pharmacology Unit, C.R.O.-National Cancer Institute, via Franco Gallini 2,
I-33081 Aviano (PN), Italy; elboustanymaguie@gmail.com (M.E.B.); lucia.scarabel@cro.it (L.S.);
mgarziera@cro.it (M.G.); concettarussospena@gmail.com (C.R.S.); lucia.destefano077@gmail.com (L.D.S.);
salis.barbara@libero.it (B.S.); gtoffoli@cro.it (G.T.); flavio.rizzolio@unive.it (F.R.)
10 Doctoral School in Molecular Biomedicine, University of Trieste, 34100 Trieste, Italy
11 Doctoral School in Chemistry, University of Trieste, 34100 Trieste, Italy
12 Department of Molecular Sciences and Nanosystems, Ca’ Foscari University, via Torino 155,
I-30172 Mestre (Venezia), Italy
* Correspondence: ggrassi@units.it; Tel: +39-040-399-6227
Academic Editors: Jean Jacques Vanden Eynde and Annie Mayence
Received: 26 February 2018; Accepted: 23 March 2018; Published: 28 March 2018


Abstract: Despite the advances in anticancer therapies, their effectiveness for many human tumors
is still far from being optimal. Significant improvements in treatment efficacy can come from the
enhancement of drug specificity. This goal may be achieved by combining the use of therapeutic
molecules with tumor specific effects and delivery carriers with tumor targeting ability. In this regard,
nucleic acid-based drug (NABD) and particularly small interfering RNAs (siRNAs), are attractive
molecules due to the possibility to be engineered to target specific tumor genes. On the other hand,
polymeric-based delivery systems are emerging as versatile carriers to generate tumor-targeted
delivery systems. Here we will focus on the most recent findings in the selection of siRNA/polymeric
targeted delivery systems for hepatocellular carcinoma (HCC), a human tumor for which currently
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available therapeutic approaches are poorly effective. In addition, we will discuss the most attracting
and, in our opinion, promising siRNA-polymer combinations for HCC in relation to the biological
features of HCC tissue. Attention will be also put on the mathematical description of the mechanisms
ruling siRNA-carrier delivery, this being an important aspect to improve effectiveness reducing the
experimental work.
Keywords: optimized drug delivery; siRNA; HCC.
1. Introduction
Antisense oligonucleotides, triplex forming-oligo-nucleotides, ribozymes, DNAzymes, antisense
oligonucleotides, aptamers, long non-coding RNAs, siRNAs and miRNAs belong to an attractive
class of molecules collectively named nucleic acid-based drugs (NABDs) [1–6]. Despite the different
mechanisms of actions, all these molecules can interact, in a sequence-related fashion, with the target
that, depending on the different NABDs, can be represented by a nucleic acid or a protein. Because
of the ability to interact virtually with all biological molecules in the cells, NABDs can regulate the
pathological functions of aberrantly expressed/functioning biological molecules. Thus, NABDs have
a great therapeutic potential. Nowadays, among NABDs, siRNAs (small interfering RNA) are the
molecules mostly investigated as potential therapeutics. In this regard, many hopes are placed on
siRNAs to combat the second cause of death in the industrialize Countries, i.e., tumors. Despite
recent therapeutic improvements, for many human tumors including hepatocellular carcinoma (HCC),
effective therapeutic approaches are not available.
In this review, we will concentrate on the description of the therapeutic potential of siRNAs
and related delivery systems against HCC. After a brief description of HCC (Section 1.1) and siRNA
(Section 1.2) features, we will summarize the barriers a siRNA has to overcome before reaching the
target (Section 2). Then, we will describe the possible solutions to minimize siRNA delivery difficulties
(Section 3) putting particular emphasis on the specific HCC related delivery issues (Section 4). Finally,
we will describe some experimental applications of siRNA/delivery systems to HCC (Section 5).
1.1. HCC
HCC is the most frequent primary malignant neoplasm of the liver and one of the most lethal
human cancer types [7]. HCC is currently the second cause of cancer death and the sixth most
commonly diagnosed cancer worldwide [8]. HCC prognosis is very poor with a 5-year overall survival
rate estimated at less than 12% [9]. Global variations in incidence rates of this cancer closely reflect the
differences in HCC risk factors distribution among developed and developing countries [10]. Alcoholic
liver disease (ALD) which can progress to cirrhosis, hepatitis C virus (HCV) infection and non-alcoholic
fatty liver diseases (NAFLD) are common risk factors in Europe, Northern America and Japan. ALD
and HCV infection, either alone or in combination, are responsible for more than two-thirds of all
HCC cases in the Western world [11]. Regardless of the etiological cause, cirrhosis is the strongest
predisposing factor being associated with the development of HCC [12]. In Asia and sub-Saharan
Africa, exposure to dietary aflatoxin B1 associated with chronic hepatitis B virus (HBV) or HCV
infections, is an important risk factor for the observed high rate of HCC [13,14]. Others risk factors for
HCC development are the use of tobacco, autoimmune hepatitis, alpha-1 antitrypsin deficiency and
hereditary hemochromatosis [13].
HCC, characterized by aberrant and exuberant angiogenesis with anomalous cell cycle control and
evasion from apoptosis [15], displays high resistance to chemotherapy and radiation treatments [16,17].
Surgical resection, transplantation and ablation are treatments restricted to very early stages of the
disease [18,19]. The first line systemic chemotherapy approved by FDA is based on the use of Sorafenib.
This is an oral multi-kinase inhibitor blocking Raf/MEK/ERK pathway and other extracellular
Molecules 2018, 23, 777 3 of 24
receptor tyrosine kinases. Sorafenib can also be administered via trans-arterial chemoembolization
(TACE) [20,21]. TACE involves the combination of the selective injection through the hepatic artery
of antineoplastic agents such as sorafenib with the selective obstruction of tumor feeding vessels.
However, sorafenib clinical advantage is modest, prolonging both relapse-free survival and overall
survival by only 2–3 months with a response rate of less than 5% [17,22].
1.2. siRNA
siRNAs are short double-stranded RNA molecules approximately 22 nucleotides long. They can
be of intracellular (endo-siRNA) or exogenous origin, being in this last case generated from invasive
nucleic acids such as viruses and transposons [23] or introduced for research purposes. With regard to
their mechanism of action (Figure 1), of the two filaments forming siRNAs, one (antisense strand) is
up-taken by a cellular protein complex termed RISC (RNA-induced silencing complex), while the other
(sense strand) is not up-taken by RISC and is discarded. The antisense strand drives RISC to a target
RNA via a perfect sequence complementarity to the target RNA. This results in the RISC-mediated
degradation of the target RNA with the consequent down-regulation of gene expression. siRNA can
be chemically generated and effectively used to target gene mRNA causing disease as shown by many
works [3,24–29].
Figure 1. siRNA mechanism of action. The antisense strand of the siRNA is up-loaded by the catalytic
protein complex RISC (RNA-induced silencing complex), while the sense strand is discarded. The antisense
strand drives RISC to a target complementary mRNA, resulting in the specific RISC-mediated cleavage
and subsequent degradation by cellular RNAses.
2. The Delivery Problems of siRNAs
Despite the great therapeutic potential of siRNAs, their practical use is limited by the chemical
nature that does not allow the administration in the naked form. When released systemically, siRNAs
encounter blood nucleases, which can induce their rapid degradation (Figure 2). Additionally, naked
siRNAs tend to be eliminated by the phagocytic system, by kidney filtration [30] and, depending
on the sequence, to activate the innate immunity [31]. The fraction of siRNAs that escapes the
above obstacles has the problem to cross the vessel wall (extravasation) and the cellular membrane.
Cell membrane crossing is hindered by the electrostatic repulsion between the negatively charged
phosphate groups present in siRNAs and the negatively charged surface of cellular membranes.
In addition, the hydrophilic nature of siRNA obstacles the crossing of the hydrophobic layer of the cell
membranes. The fraction of siRNA escaping the above obstacles has to face the problem of cytosolic
nucleases that can further reduce the number of active molecules. Finally, proper cellular trafficking,
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i.e., endosomal escape [32], has to be accomplished. If siRNAs are sequestered into endosomes, they do
not have the possibility to get in contact with their targets, thus drastically impairing if not abolishing
the biological effect(s). Thus, it is clear that if administered as naked molecules, siRNAs have no
possibility to exert any therapeutic function.
Figure 2. Biological barriers to siRNA delivery. For systemically released siRNAs the first obstacle is
represented by blood nucleases, which can induce their degradation. The siRNAs have then problem to
cross the vessel wall (extravasation) then the ECM (Extra Cellular Matrix) and finally the cell membrane.
Once into the cell, siRNAs have to evade from endosome.
3. General Strategies to Optimize siRNA Delivery
Two main strategies are commonly followed to minimize the delivery obstacles of exogenously
synthesized siRNAs. One possibility consists of the chemical modification of siRNA structure to make
it resistant to degradation [4]. The other possibility is to complex siRNA with synthetic vectors able
to bind, protect and allow the delivery to the target cells [4]. In this way, a nanostructured system
can permit to increase tumor accumulation thus improving siRNA efficacy [33–36]. Often the two
strategies are adopted together even if some chemical modifications may impair siRNA effectiveness.
Thus, caution should be taken in the use of siRNA chemical modification(s). Here we will concentrate
on the siRNA complexation with synthetic vectors [6,37–40] and in particular on polymeric-based
vectors. These vectors are commonly used as siRNA delivery materials because of their versatility,
biocompatibility and low cost. Polymers can provide siRNA protection against nucleases, allow ECM
and cell membrane crossing and, when equipped with smart moieties, direct the siRNA to the target
cells. A general description of the most commonly used polymers is reported below.
3.1. Polymers for siRNA Delivery
Polymers have been used in siRNA delivery due to: (1) the relatively low costs of production/isolation,
(2) the possibility to undergo a wide range of chemical modifications that allow the optimization for the
specific application, (3) the fact that they are biocompatible, biodegradable and have low immunogenic
properties. Most commonly used polymers for siRNA delivery to HCC are Chitosan (CH), Inulin, PEI
(Polyethylenimine), PEG (Polyethilenglycole), Polycaprolactone (PCL), and cyclodextrin (CD). Whereas CH
and Inulin are natural polymers, PEI, PEG, PCL and CD, are of synthetic origin. Often these polymers are
used in combination with each other or even with other different molecules to improve delivery properties.
The high plasticity of the molecular structure of polymers is probably at the base of their success
as delivery systems for different drugs including, but not limited to, siRNAs. A relevant variable to be
considered when developing siRNA-polymers complexes deals with the net superficial charge of the
particles. Both anionic and cationic complexes usually display proper solubility and stability in the
physiological environment. However, strongly anionic complexes can have difficulties in transfecting
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cells in virtue of the electrostatic repulsion with the negatively charged cell membrane. Excessively
strong cationic complexes bind greedily to cell membrane due to potent electrostatic interactions;
this, however, can lead to non-specific cellular uptake [41] and cause membrane disruption with
consequent cell death. Thus, the surface electric charge has to be finely tuned to have optimal
transfection with low unspecific cytotoxicity.
CH is produced commercially by deacetylation of chitin, the structural component present in
the exoskeleton of crustaceans and cell walls of fungi. CH has been considered as a delivery material
because of its unique physicochemical and biological characteristics [42]. It is a linear polysaccharide
with a carbohydrate backbone containing two types of repeating residues, 2-amino-2-deoxy-glucose
(glucosamine) and 2-N-acetyl-2-deoxy-glucose (N-glucosamine), linked by (1-4)--glycosidic linkage
(Figure 3A). The primary hydroxyl and amine groups located on the backbone of CH allow chemical
modification in order to control the physical properties. Moreover, the amino groups confer to CH
a positive charge. This favors the electrostatic binding with siRNAs, which, containing phosphate
groups in their structure, are negatively charged. Thus, CH can confer protection to siRNA driving
it to the target cells. However, CH tends to suffer from the low transfection efficiency and low
solubility. The conjugation with other molecules such as PEI and PEG can easily circumvent the
problem. Alternatively, the physicochemical and biological properties of CH can be tuned by varying
the degree of the acetylation and/or modifying the molecular weight [43].
Figure 3. Polymers employed as siRNA delivery materials: chemical structures.
PEI is a synthetic polymer with repeated units composed of amine groups and two carbon
aliphatic CH2–CH2 spacer (Figure 3B). PEI can exist both in linear or branched forms. In the linear
form, it contains all secondary amines; in contrast, branched PEI contains primary, secondary and
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tertiary amino groups. PEI is produced on industrial scale and finds many applications mostly due to
its poly-cationic nature. Even if PEI tends to be more cytotoxic than natural polymers [44], it is one
of the most used cationic polymers in the bio-medical field. The ability to transfer nucleic acids to
the cell is superior for high molecular weight PEI compared to low molecular weight PEI. However,
high molecular weight PEI displays somewhat more cytotoxic effects compared to low molecular
weight PEI. The addition of hydrophilic and hydrophobic segments or cell/tissue-specific ligands [45]
can however significantly reduce cytotoxicity. Because of the positively charged amino-groups, PEI can
efficiently bind negatively charged siRNAs. Additionally, due to its “proton sponge effect”, PEI favors
siRNA endosomal escape [46].
PEG is a synthetic polyether compound also known as polyethylene oxide (PEO) or polyoxyethylene
(POE), depending on its molecular weight. Commonly, its structure is represented by the formula
H−(O−CH2−CH2)n−OH (Figure 3C). PEG, considered to be non-toxic and safe [47], is widely used due
to the solubility in an aqueous environment and organic solvents. PEG addition (PEGylation) reduces
toxicity and stabilizes the delivery particles [48]. PEG can be also used as anchor for specific ligands to be
fixed on the surface of delivery particles [49].
PCL is a polyester of synthetic origin [50], produced by the ring opening polymerization of the
cyclic monomer "-caprolactone in the presence of a catalyst (Figure 3D). PCL is biodegraded via the
hydrolysis of its ester linkages in physiological conditions. Once biodegraded, it is fully excreted
from the body. For this reason, it received a great deal of attention as an implantable/drug delivery
biomaterial, applications for which FDA has approved it. Additionally, PCL can be used to tune the
physical, chemical and mechanical properties of different materials when co-polymerized, for example,
with polymers such as PEG.
Inulin is a natural storage carbohydrate present in many plant species [51]. Fructose units, joined
by a (2→1) glycosidic bond, with a terminal glucose (Figure 3E) compose the polymer. Inulin is
used in many food applications and more recently in pharmaceutical applications. For example,
inulin can be used to improve the water solubility of various poorly soluble drugs. Additionally,
chemically modified inulin can be used in the controlled delivery to the colon. This is possible as inulin
is hydrolyzed only by inulinases produced by bifidobacteria in the colon and not by the digestive
enzymes in the upperparts of the gastro intestinal tract. We have recently shown that inulin conjugated
with diethylenetriamine is suitable as a carrier for therapeutic delivery of siRNAs [52].
Cyclodextrins (CDs) are a series of natural cyclic oligosaccharides composed of 6, 7 or 8 D-glucose
units linked by -1,4-linkages and named -, -, or -CD. CDs are characterized by a truncated cone
shape with the internal cavity being hydrophobic (Figure 3F) while the outer part is hydrophilic.
The cavity depth depends on the CD type being around 0.7 nm, 0.78 and 0.9 for -CD, -CD and -CD,
respectively. This cavity can host various molecules to form supra-molecular inclusion complexes.
The most commonly used form of CD is -CD that is equipped with amphiphilic and cationic residues.
The presence of positively charged residues allows the interaction with the negatively charged siRNAs.
CD are commonly inserted in polymeric structures such as a linear or branched polymer thus resulting
in delivery vectors characterized by low cytotoxicity and effective transfection ability [53].
From the examples above reported it is evident that electrostatic interaction are at the base of
the interaction between cationic copolymers. Following binding to the polymers, siRNA half-life and
cell entry are greatly favored. For siRNA delivery, polymers can be also used in the form of more
complex structures named micelles. Single units (unimers) make up these structures. The hydrophilic
portion of the unimers is in contact with the external aqueous environment while the hydrophobic one
stays in the inner part of the micelles (Figure 3G) [4]. To obtain unimers with such an amphipathic
property polymers are conjugated with, for example, stearic acid (SA), a saturated fatty acid with
an 18-carbon chain. This kind of modification can thus confer a great plasticity to polymers [54].
Other cationic polymers able to form micelles in solution are PEG and poly(propylene sulfide). Example
of hydrophobic polymers are PCL, polylactide (PLA) and poly(lactic-co-glycolic acid) (PLGA).
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4. Specific Strategies to Optimize siRNA Delivery to HCC
In addition to the above-reported strategies useful to improve in general siRNA delivery, other
specific aspects should be considered for siRNA delivery to HCC cells. In particular, vascular, physical
and molecular aspects need consideration (Figure 4).
Figure 4. Specific aspects related to an optimized siRNA delivery to HCC.
4.1. Vascular Aspects
Whereas HCC is mostly nourished by arterial vessels, the normal liver is mainly supplied by
vein vessels [55]. Notably, the arterial supply in HCC increases with the progression of the disease
being moderate in initial lesions and becoming preponderant in advanced HCC [56]. This shift occurs
to meet the higher requirement of nutrition and oxygen of bigger and advanced HCC lesions. Thus,
to target HCC and preserve the normal liver tissue, it would be desirable to consider an arterial
delivery for siRNA in the advanced stages of the disease. In this regard, the use of TACE [57] can be
considered an appropriate approach for siRNA delivery. TACE is a minimally invasive procedure
performed in interventional radiology to restrict the HCC blood supply. Small embolic particles coated
with chemotherapeutic agents are injected selectively into an artery directly supplying the tumor thus
targeting mostly HCC cells but not normal hepatocytes. In this regard, in animal models of HCC, trans
arterial drug delivery resulted: (1) to be safe both for the liver and for distant organs, (2) to display
preferential tumor uptake of the anti-cancer drug and (3) to have high tumor response [58]. With regard
to the delivery of siRNA, an anti hypoxia-inducible factor-1 (HIF-1-siHIF-1) was released by a
trans arterial embolization procedure complexed within a iodized oil emulsion [59]. HIF-1, a pivotal
transcription factor synthesized by tumor cells under hypoxic conditions, regulates the expression of
relevant genes for the survival of cancer cells. The combination of trans arterial embolization with
siHIF-1 resulted to be effective in slowing down tumor progression and improving animal survival.
In addition to the dissimilar vascularization, HCC differs from the normal liver because of
the different structure of the nourishing vessels. HCC vessels are characterized by an unusual
leakiness, [60], giving origin to the well known as enhanced permeability and retention (EPR) effect [61].
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This is due to the presence of intercellular fenestrae in the vessel wall of about 1.7 m [62]. Additionally,
the frequent absence of pericytes and/or vascular smooth muscle cells around the endothelial layer,
contributes to the leakiness of the tumor vessels. Thus, HCC vessels are more prone to allow the
extravasation of particles around 1 m in diameter compared to the normal liver vessel where fenestrae
size is significantly smaller. Additionally, it has been reported that particle of about 1–3 m in
diameter [63] are mostly confined in proximity of the endothelial cells of the vessel; in contrast, smaller
particles tend to stay more in the middle of the vessel. Thus, extravasation is favored for 1–3 m
particles compared to smaller particles. Moreover, m size particles are not removed by the kidney,
which has a smaller cut off (8 nm) [64,65].
4.2. Phagocytosis
Despite the above advantage of the 1–3 m particles, it should be reminded that particles bigger
then 0.2 m are readily scavenged non-specifically by macrophages [66]. In the liver, phagocytosis,
mostly exerted by Kupffer cells, is particularly increased due to the reduced blood flow (200–800 m·s−1
compared to 10–100 cm·s−1 in veins [67] in hepatic sinusoid compared to other body vessels.
The charge of the nanoparticle surface can also influence phagocytosis. In general, nanoparticles
with highly positive or negative charges are more prone to phagocytosis due to serum protein
absorption [68]. To minimize the uptake by the liver cells different form HCC cells, PEGylation is often
followed. PEGylation reduces nanoparticle binding to serum protein (such as immunoglobulin) thus
impairing macrophage uptake. However, it should be considered that also nanoparticle shape plays
a role in phagocytosis. It has been shown that while spherical nanoparticles undergo phagocytosis,
disc-like and cylindrical nanoparticles more successfully evade phagocytosis [69]. Reducing serum
protein binding to nanoparticles has also the advantage to minimize unwanted variation in size,
surface charge and aggregation of the nanoparticles. Serum protein can indeed significantly affect
nanoparticle fate. Albumin can prolong blood nanoparticle circulation [70] and displace negatively
charged molecules such as siRNAs. On the other hand, binding to the positively charged fibrinogen
can alter the surface charge and improve phagocytosis [71].
Finally, it should be considered that all the above aspects are particularly problematic when
administering the nanoparticles systemically; however, a local administration via TACE, feasible in
HCC, can significantly minimize most of them.
4.3. Physical Aspects
As in most other tumors, defective neo-vasculature of HCC determines ineffective oxygen delivery,
especially in the inner regions of the tumor. This implies that HCC cells can obtain their energy mostly
from the biochemical pathway that can work in low oxygen, i.e., glycolysis [72]. The increased
glycolytic rate is invariably associated with the increased production of lactic acid. This, together with
the reduced H+ removal by the defective neo-vasculature, determines a reduction in pH within the
tumor. Thus, it may be possible to take advantage of this feature by creating siRNA delivery systems
able to preferentially release siRNA in low pH [73].
Another physical aspect to be considered for effective siRNA delivery is the interstitial fluid
pressure (IFP). The liquid phase present between the newly formed tumor vascular wall and the
plasma membrane of the neoplastic cells is responsible for the IFP phenomenon [74]. IFP is higher
in the center of the tumor rapidly diminishing towards the tumor periphery. The reasons for IFP are
multiple and include vessel abnormalities, diminished function of lymphatic vessels [75] and the EPR
effect [76]. The occurrence of this center-periphery gradient of the liquid pressure in many tumors
including HCC [74], determines a mass flow movement of fluid away from the central region of tumor.
This phenomenon obviously reduces the amount of drug (including siRNA) that can reach the inner
part of the tumor. On the other hand, moving to the inner part, the amount of necrotic cells increases
due to the low oxygen concertation. Thus, it may be not so crucial to reach necrotic cells; in contrast,
reaching the vital tumor cells closer to the periphery may be more relevant.
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The extracellular matrix (ECM) of many tumors tend to be denser than in the normal corresponding
tissue. This is mostly due to the deregulation of ECM protein/glycoprotein/proteoglycan interaction [77].
A possibility to minimize the shielding effect of tumor-specific ECM is to minimize particle size and/or
equip the particles with ECM proteases [78]. It should be noted however, that in the case of HCC, ECM is
not particularly dense [79] and thus this barrier may not represent an insurmountable obstacle. Despite
this, further investigation about the physical characteristic of HCC ECM are required (work in progress).
4.4. Molecular Aspects: Targeting Surface Antigens of HCC Cells
Optimal HCC delivery systems for siRNA should take into account the above aspects. However,
this might not be sufficient for the development of an effective and specific delivery approach for HCC.
The generation of delivery systems equipped with smart moieties able to recognize specific antigens
on HCC cells is considered extremely relevant. This strategy can significantly contribute to restrict the
delivery of therapeutic molecules to HCC cells, leaving the normal hepatocyte un-affected.
Different molecules predominantly expressed by HCC cells compared to normal hepatocytes
have been considered so far as possible targets (Table 1). Among this, Asialoglycoprotein receptor
(ASGP-R) is a glycoprotein mostly presents on the hepatic cell surface [80]. Notably, it is overexpressed
on the surface of HCC cells [81]. ASGP-R is capable of recognizing and binding galactose terminal and
galactosamines residues. Because of its restricted expression, ASGP-R is considered a valuable surface
biomarker to target HCC cells [82].
Table 1. Specific surface antigens on HCC cells.
Extended Name Abbreviation References
Asialoglycoprotein receptor ASGP-R [80–82]
Glypican-3 GPC3 [83,84]
Transferrin receptor TfR [85–87]
Folic acid receptor FR [88]
Epidermal growth factor receptor EGFR [89]
v3 and v5 integrins [90]
Scavenger receptor class B type I SR-BI receptor [91]
Homodimeric glycoprotein AF-20 antigen [92]
Another target is Glypican-3 (GPC3), a member of membrane-bound heparin sulfate proteoglycans.
Nowadays GPC3 is considered a highly specific marker for HCC [83]. However, its expression is not
limited to HCC as it is present also on other tumor cells such as squamous cell carcinoma of the lung
and testicular non seminomatous germ cell tumors [84].
Transferrin receptor (TfR), a transmembrane glycoprotein, is involved in the uptake of the
iron-carrying protein named transferrin [85]. Whereas TfR is poorly expressed by normal cells,
in proliferating cells its expression rises significantly [86]. Moreover, TfR-2, a newly identified member
of TfR family, was found to be preferentially expressed in hepatocytes and enterocytes of the small
intestine [87]. Thus, TfR-2 better than TfR, may be considered a specific ligand to target hepatocytes.
The folic acid (FA) receptor (FR) is a 38 kDa glycosyl-phosphatidylinositol membrane-anchored
glycoprotein. Whereas it is overexpressed in various cancers, its expression in normal tissues is
considerably reduced compared to tumor tissues. This distinct expression pattern makes it an ideal
target for tumor drug delivery. Moreover, it has been extensively studied in targeted drug delivery
due to its inherent high affinity and small size [88].
Epidermal growth factor receptor (EGFR), also known as ErbB1 or HER-1, is a classical
transmembrane receptor tyrosine kinase. It is activated by several ligands, which in turn trigger
different pathways controlling proliferation, differentiation and survival. Notably, human carcinomas
frequently express high levels of receptors in the EGFR receptor family, and their overexpression has
been associated with a more aggressive clinical behavior [89].
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Integrins are transmembrane receptors involved in cell-ECM adhesion. Upon ligand binding,
integrins activate signal transduction pathways that regulate many relevant cellular processes such
as cell proliferation. Notably, the v3 and v5 integrins are overexpressed on the angiogenic
endothelium in different malignant tumors [90] including HCC. Thus, by equipping a delivery system
with the tripeptide arginine glycine aspartic acid (RGD) motif that is bound by v3/v5 integrins,
it may be possible to direct therapeutic siRNAs to HCC.
The scavenger receptor class B type I (SR-BI receptor) is a multi-ligand cell surface receptor
expressed on both macrophages and liver cells [91]. It facilitates the uptake of cholesteryl esters from
HDL. Thus, it drives cholesterol from tissues to the liver in the various stages of reverse cholesterol
transport pathway. By preparing a delivery vector able to target SR-BI receptor, it may be possible to
gain HCC targeting.
Despite being in principle of interest for liver targeting, the above mentioned molecules are mostly
expressed on both normal liver and HCC cells, although at different levels. Thus, a real discrimination
between healthy and HCC cells is not fully reachable. This limitation does not seem to apply for
the homodimeric glycoprotein (AF-20 antigen) which is expressed on HCC but not on normal liver
cells [92]. A completely novel approach may be based on the use of specific aptamer binding to
unknown HCC specific antigen. Aptamers are represented by single-stranded sequences of DNA or
RNA with the ability to specifically interact with a target molecule. The specific aptamer folding is
responsible for the possibility to link the target molecule; thus, almost no Watson-Crick base pairing
occurs between the aptamer and the target. The fact that aptamers are small, easy to select, can be
directed against any target, are cheap to produce, are stable and are not immunogenic [93], confers to
these molecules a great advantage compared to antibodies. To date, an aptamer (TLS11a) has been
shown [94] to bind HCC cells specifically. The effectiveness of this approach needs further confirmation.
4.5. Molecular Aspects: Targeting HCC Specific Oncogenes
The above discussion indicates that ideal HCC markers have not yet unequivocally identified.
Indeed, most of them are also present on normal liver cells. Thus, a complete discrimination between
HCC cells and normal hepatocytes cannot be guaranteed. However, an increased level of targeting
specificity can be achieved using siRNA directed against cellular genes/pathway expressed/activated
predominantly in HCC cells. This implies that, even if a siRNA reaches a healthy hepatocyte, it may
not exert major detrimental effects as the target gene is not/poorly expressed. Below, some possible
examples of HCC specific oncogenes are discussed.
eEF1A, a protein involved in the elongation step of protein synthesis [95], has two isoforms,
eEF1A1 and eEF1A2. In addition to the role in translation, both eEF1A isoforms possess other functions
relevant for many cellular processes such as cell cycle and apoptosis [96]. eEF1A1 is expressed in
almost all human tissues; in contrast, eEF1A2 expression is confined to skeletal muscle, heart and
nervous system with no expression in the normal liver. We reported that eEF1A2 is overexpressed in
human HCC cell lines and that its overexpression correlates with cancer cell growth and differentiation
phenotype [97]. eEF1A2 overexpression has been also detected in HCC human tumor specimens [98,99]
and its role in HCC development has been proved [100]. The fact that eEF1A2 is not expressed in the
normal liver but its expression is pathologically turned on during HCC development, suggests that
an anti eEF1A2 siRNA may exert its effect in HCC cells but not in normal hepatocytes. Thus, even if
the delivery vector cannot perfectly discriminate between HCC and normal hepatocytes, detrimental
effects on healthy hepatocytes are not expected due to the lack of eEF1A2 expression.
E2 promoter binding factor 1 (E2F1) [101], belongs to a family of transcription factors named
E2Fs [102]. E2F1 is a transcription factor implicated in the regulation of many cellular processes
including cell migration, differentiation, metabolism, cell reprogramming and proliferation. With regard
to cell proliferation, E2F1 triggers the G1/S phase transition of the cell cycle by promoting the expression
of genes such as cyclin E and cyclin A. Thus, E2F1 is considered a pivotal regulator of the initial
stages of cell proliferation. Whereas its expression is ubiquitous in human tissues, the biological
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effects are somewhat tissue-dependent. It has been reported that E2F1over-expression does not confer
any growth advantage to hepatocytes following surgical elimination of two-thirds of the liver [103].
Additionally, it has been [104] suggested that another E2F family member, E2F-4, rather than E2F1 is
critical for liver cell growth. In contrast to the normal liver, E2F1 plays a documented role in HCC
development [102] where it is overexpressed. Due to the E2F1 features, it is reasonable to speculate
that its siRNA-mediated silencing may predominantly affect the growth of HCC cells leaving normal
hepatocytes substantially unaffected.
Whereas eEF1A2 and E2F1 are not the only smart targets for HCC as other may exist [105], it is
clear that a double level of targeting specificity should be pursued, i.e., the use of targeting moieties
on the delivery system and the employment of siRNA directed against the mRNA of specific HCC
genes/pathways.
4.6. Description of siRNA Activity by Mathematical Modeling
Based on all the above considerations, the major steps for nanoparticle delivery to HCC are:
circulation in the blood, accumulation in the tumor area, internalization into tumor cells followed by
the siRNA release [106]. Whereas these variables can be investigated independently at the experimental
level, for a comprehensive determination of the delivery effectiveness, mathematical modeling can be of
great value. Although the mathematical description of such a complex phenomenon is not an easy task,
it can provide important indication on how to optimize delivery by reducing the time-consuming and
expensive experimental part. In this regard, the model built up by Bartlett and Davis [107] represents
a powerful theoretical tool to describe siRNA-complex fate, once injected in the blood stream. Indeed,
these authors recur to a set of twelve ordinary differential equations aimed to estimate the temporal
evolution of the concentration of twelve very important quantities. These are the plasma free (SC) and
bound (to plasma protein, SCB) siRNA-complex concentration, siRNA-complex concentration in the
extracellular environment close to target cells (SCT), siRNA-complex and free siRNA concentration
inside cell endosomes and cytoplasm (SCE, SE, SCC and SC, respectively), activated RISC (RNA-induced
silencing complex) complex concentration free and bound to target mRNA (RC* and Rm, respectively),
target mRNA (CmRNA), protein (Pr) concentration and cells number (Nc). This model is organized into
four modules that can be changed independently to modify model complexity as desired. The first
module deals with siRNA “circulation/extracellular transport” (three equations), the second is about
siRNA “cellular uptake and intracellular trafficking” (four equations), the third describes the fate of
free and bound activated RISC (three equations) according to the Micaelis-Menten multiple turnover
mechanism and the fourth focusses on “cell growth and target protein production” (two equations):
Circulation/extracellular transport:
dSCB
dt
= KPBSC− KPUSCb (1)
dSC
dt
= KPUSCB −
(
KPB + K
P
EL + XscKt
)
SC (2)
dSCT
dt
= XscKtSC−
(
KTEL + Kint
)
SCT (3)
Cellular uptake and intracellular trafficking:
dSCE
dt
= Kint
VE
VI
SCT −
(
dil + KEU + K
E
esc
)
SCE (4)
dSE
dt
= KEUSCE −
(
dil + KES−d + K
E
S−esc
)
SE (5)
dSCC
dt
= KEescSCE −
(
dil + KCU
)
SCC (6)
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dSC
dt
= KCUSCC + K
E
S−escSE + K
C
RISK−bRC
∗ −
(
dil + KCS−d
)
SC − KCRISK− f SC(Rtot − RC∗ − Rm) (7)
Micaelis-Menten multiple turnover mechanism:
Cell growth and target protein production:
dPr
dt
= KPrf CmRNA − KPrd Pr (8)
dNc
dt
= KgNc
(
1− Nc
Ncmax
)
(9)
where t is time, KPB , K
P
U , K
P
EL are, respectively the binding, unbinding and elimination siRNA-complex
constants in the plasma environment, Xsc is the effective dose fraction available to target cells, Kt
is a kinetic transfer constant affecting siRNA-complex flux to tissues close to target cells, Kint is the
internalization constant inside target cells, KTEL is the elimination siRNA-complex constant in the
tissues close to target cells, VE and VI are, respectively, extracellular volume and intracellular volume,
dil is the dilution rate due to cells division, KEU and K
C
U are, respectively, the siRNA-complex unbinding
constants inside endosomes and cytoplasm, KEesc and KES−esc are, respectively, the kinetic constant
ruling siRNA-complex and free siRNA transfer from endosomes to cytoplasm, KES−d and K
C
S−d are,
respectively, the free siRNA degradation constant inside endosomes and cytoplasm, KCRISK− f and
KCRISK−b are, respectively, the forward and backward kinetic constants ruling RISK activation, Rtot is
the total concentration of RISC complex, KC1 , K
C
−1 and K
C
cut are the Micaelis-Menten kinetic constants,
KCRISK−d, K
C
mRNA−d and K
C
Rm−d are, respectively, the activated RISK, mRNA and Rm degradation
constants inside cytoplasm, KPrf .and K
Pr
d are two kinetics constants ruling the protein concentration
time dependence, Kg is a constant ruling the cells number time variation and Ncmax is the maximum
admissible cells number.
Interestingly, from a physical point of view, the delivery process can be subdivided into two
distinct phases: the external one, involving the first module, and the cellular one, involving the other
three modules. Thus, in the case of in vivo experiments, all the four modules are needed, while only
the last three modules matter in the case of simpler in vitro experiments.
One of the major merit of this model relies on the possibility of evaluating the timely evolution of the
target RNA and protein both in in vitro and in vivo experiments. This is a very important achievement
as it allows comparing theoretical predictions with experimental data. In turn, this model permits the
estimation of many parameters having a precise scientific meaning such as the Micaelis-Menten constants.
Figure 5 shows, as an example, the temporary trend of the target protein (expressed as the % of the
initial value) and the number of cells (expressed as the % of the maximum number of cells) after a single
administration of siRNA-complex. It is clear that the effect of siRNA-complex is to initially reduce the
amount of the target protein whose concentration reaches a minimum after, about, four days. Then, due to
siRNA-complex degradation and the continuous dilution due to cell growth, the amount of the target
protein comes back to its original value.
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Figure 5. Temporary evolution of the % of target protein (solid line) and the % of cells number
(dashed line) according to the Bartlett & Davis model (model parameters are those reported in
Bartlett & Davis [107]).
The aspect of the model that needs to be implemented deals with the evaluation of siRNA-complex
dilution due to cell replication. Indeed, the assumption of a constant dilution does not seem realistic as
dilution depends on the number of cells that, in turn, relies also on the effect exerted by siRNA on the
target RNA/protein whose abundance reflects the cell replication speed. Thus, we are working on a
model implementation accounting for an intrinsically variable dilution. Despite this, it is evident that
the mathematical modeling of the entire process can contribute to better understand the phenomenon
and, especially, to guide the experiments.
5. Strategies Utilized to Deliver siRNA to HCC
Among the several studies aimed at the delivery of therapeutic siRNAs to HCC, here we will
concentrate on the strategies based on targeted systems (Tables 2 and 3).
5.1. In Vitro Models of HCC
Lu Han et al. [108] developed a multifunctional vector for oral administration consisting of
galactose modified trimethil chitosan-cysteine (GTC) conjugates. The galactose residue allowed the
targeting towards ASGP-R, overexpressed on HCC cells [80–82]. Three different GTC nanoparticles
(NPs) with various galactose grafting densities were tested. NPs were loaded with anti-Survivin and
anti-VEGF (Vascular Endothelial Growth Factor) siRNAs. Survivin, transcribed from the BIRC gene,
is a protein overexpressed in most human tumors but not in normal tissues [109]. It prevents apoptotic
cell death through the inhibition of caspase activation. VEGF increases the protein level of Survivin
via the activation of PI3K/AKT pathway and promotes tumor angiogenesis [110]. The ability of the
NPs to cross the intestinal epithelium was assessed in vitro both in Caco2 cells and in Caco2 cells
co-cultured with Raji B lymphocytes. Caco2 cell line has been used to mimic the intestine epithelium;
Raji B lymphocytes mimic the lymphatic M cells of the intestine wall. The GTC NPs reversibly open
the tight junctions between Caco2 and Raji B lymphocytes cells, thus promoting transcytosis of NPs.
This suggests that in vivo, the NPs can have the ability to cross the intestinal wall. In the HCC
cell line BEL-7402, the most effective NPs displayed 1,9-fold increased uptake as compared to the
control, indicating the effectiveness of ASGP-R targeting by the galactose residue. Once internalized,
the inhibition of cell growth exerted by NPs loaded with both anti-Survivin and anti-VEGF siRNAs
was more pronounced than that induced by a single siRNA, indicating the synergistic antitumor effect.
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Table 2. In vitro targeted delivery of siRNAs to HCC.
Delivery Material HCC TargetingAntigen HCC Model
siRNA mRNA
Target Reference
Galactose modified trimethylchitosan-cystein (GTC) ASGP-R BEL-7402 Survivin andVEGF [108]
PEI grafted with stearic acid (PEI-SA) FR HuH-7 VEGF [111]
GalNac- PEG-b-PCL and PCL-b-PPEEA ASGP-R Primaryhepatocytes apolipoprotein B [112]
Inulin and diethylentriamine (Inu-DETA)
on ,-poly-(N-2-hydroxyethyl)-D,L-aspartamide (PHEA)
and DETA and PEG) and GAL molecules
(PHEA-DETA-PEG-GAL)
Trafficking
specificity JHH6 E2F1 [52]
ASGP-R JHH6 E2F1 [113]
[113]
Huang et al. [111] suggested a multifunctional polymeric micelle composed of PEI grafted with
stearic acid (PEI-SA). Moreover, the particles contained folic acid-polyethyleneglycol-block-polyglutamic
acid to improve cellular uptake. The targeting moiety was represented by FA (folic acid), which can drive
the complex to the FR (folic acid receptor), typically overexpressed in tumor cells. The nanoparticles were
used for the co-delivery of anti-VEGF siRNA and doxorubicin (DOX), a commonly used anticancer drug.
The nanoparticles display positively charged amino groups, which enable the electrostatic interaction
with the negatively charged phosphate of the siRNA. The safty, cellular uptake and specific VEGF gene
silencing ability were demonstrated in the HCC cell line HuH-7 cells.
Wang et al. [112] synthetized a micellar nano-carrier containing PEG and PCL polymers. In this
case, a N-acetylgalactosamine functionalized PEG-b-PCL (GalNac- PEG-b-PCL) and PCL-b-PPEEA
(poly(2-aminoethyl ethylene phosphate), were used. The first polymer, carrying N-acetylgalactosamine,
conferred the ability to bind to ASPG-R, thus allowing a liver targeted delivery. The second allowed
the electrostatic binding to the siRNA that was directed against apolipoprotein B. This is a liver-specific
cholesterol transport-related gene, chosen as a model target that has no directed correlation to HCC.
This study confirmed the effectiveness of the micellar di-block polymers nano-carrier approach in vitro.
We recently developed a siRNA delivery system based on inulin (Inu), an abundant and natural
polysaccharide, conjugated with diethylenetriamine (DETA) residues (Inu-DETA) [52]. Inu-DETA
polyplexes can effectively bind siRNAs, are highly cyto-compatible and, in the HCC cells JHH6,
effectively deliver a siRNA directed against the mRNA of the transcription factor E2F1. In JHH6, E2F1
silencing resulted in a marked anti-proliferative effect. We also observed that in JHH6, the mechanisms
of polymer-siRNA uptake and trafficking, i.e., micropinocytosis and clathrin mediated endocytosis,
is crucial to allow the proper siRNA cellular distribution and thus effectiveness. In contrast, in the
bronchial cell line 16HBE where the uptake mechanism (caveolae-mediated endocytosis) resulted in an
improper distribution of siRNA within the cell, no significant effects were observed. These data point
towards the relevance of the proper trafficking for efficient siRNA delivery. Moreover, they suggest
that delivery specificity may be also achieved at the trafficking level. It should be noted that our
Inu-DETA nanoparticles had no specific HCC targeting moieties but reached specificity of action with
a different strategy. Additionally, the targeting of E2F1 can confer a further level of specificity for
HCC, as discussed in Section 4.5. Finally, it is obvious that a complete targeting specificity cannot be
achieved only at the trafficking levels, as other targeting strategies have to be combined.
We also concentrated on the development of a delivery system able to recognize a specific HCC cell
antigen [113]. We prepared a cationic polymer based on ,-poly-(N-2-hydroxyethyl)-D,L-aspartamide
(PHEA) derivatized with diethylene triamine (DETA) and with a polyethylene glycol (PEG) derivative
bearing galactose (GAL) molecules (PHEA-DETA-PEG-GAL) (see also Figure 6A). A cartoon of the
polymer is reported in Figure 6A. The generated polymer had the proper features to be potentially
employed as a systemic delivery system for siRNA. Moreover, it could specifically release an anti
E2F1 siRNA to HCC cells. This property was due to the existence of GAL residues that can interact
with the ASGP-R, overexpressed on HCC cells. Notably, our polymer was effective in reducing
the mRNA and protein levels of E2F1 and of E2F1-regulated genes in ASGP-R overexpressing but
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not in ASGP-R non-expressing cells. In turn, a significant reduction in HCC cell proliferation was
achieved. Notably, removal of GAL residue almost completely abrogated the targeting specificity of
the developed polyplexes. Similarly, in ASGP-R non-overexpressing cells, polyplexes could not deliver
the siRNA.
5.2. In Vivo Models of HCC
In a recent study [114], nanoparticles containing urocanic acid-modified galactosylated trimethyl
chitosan (UA-GT) conjugates as polymeric vectors were prepared. These nanoparticles displayed
potent capabilities in encapsulating a siRNA against VEGF (siVEGF). The presence of the galactose
residue allowed a specific uptake in the HCC cell line QGY-7703 via the binding to ASGP-R. Moreover,
the urocanic acid residues improved the buffering capacity thus allowing a more efficient release from
endosomes. For in vivo testing, a HCC mouse xenograft subcutaneous model of HCC was used. 200 g
of siVEGF/kg were administered systemically once every four days for a total of five times. siVEGF
loaded nanoparticles significantly reduced tumor growth and significantly decreased the density of
blood vessels demonstrating the anti angiogenic effects of the nanoparticles. Notably, the authors did
not observe a significant loss in body weight and histological damage in the liver and other major
organs. In line with this, the hematologic and hepatic function parameters were not significantly
affected. Together, the above data suggest that the UA-GT nanoparticles were effective and potentially
safe for in vivo use.
Nanoparticles containing galactose-modified trimethyl chitosan-cysteine (GTC) conjugates [108]
were used for the active targeting of ASGP-R. Nanoparticles loaded by anti-Survivin and anti VEGF
siRNAs, were administered orally in a xenograft mice model of HCC. Trimethyl and cysteine groups
of GTCs improved intestinal adhesion also promoting tight junctions opening. The galactose ligands
allowed active internalization into HCC cells. Tumor growth rate was evidently reduced with no
relevant cytotoxicity. In a variation of the above experiment, a series of GTCs polyplexes with distinct
siRNA binding affinity were produced by modifying the composition of different ionic crosslinkers
such as sodium tripolyphosphate (TPP) and -polyglutamic acid (-PGA) [115]. A cartoon of the
GTC/TPP/-PGA polymer is reported in Figure 6B. In this case, only an anti VEGF siRNA was loaded.
In xenograft mouse models of HCC, GTC polyplexes demonstrated to be safe and to significantly
down regulate tumor angiogenesis causing a remarkable tumor growth arrest.
Figure 6. Cont.
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Figure 6. (A) Schematic representation of the polymer from ref. [113]; PHEA:
,-poly-(N-2-hydroxyethyl)-D,L-aspartamide, DETA: diethylene triamine, PEG: polyethylene
glycol, GAL galactose, siRNA: small interfering RNA, ASGP-R: Asialoglycoprotein receptor;
(B) Schematic representation of the polymer from ref. [115]. GTC: galactose modified trimethyl
chitosan-cysteine, TPP: sodium tripolyphosphate, -PGA: -polyglutamic acid; on the left are shown
the single components, on the right the assembled particle.
In a recent study [116], a magnetic resonance imaging (MRI)-visible vector that incorporated
FA-modified SPION (superparamagnetic iron-oxide nanoparticles) for the targeting to FR was
developed. SPION, composed by iron-oxide in the form of maghemite (-Fe2O3), are nanoparticles
with low toxicity as they are contained in ferritin, the physiological storing protein of iron in the
human body. They have the property of being superparamagnetic, which means that in the presence
of an external magnetic field, they become magnetized and can be entrapped/visualized into the
region where the magnetic field is applied. PEG and PEI were used to allow FA and siRNA binding to
the nanoparticles thus resulting in FA-PEG-g-PEI-SPION complexes. The mRNA of the transducin
beta-like 1 X-linked receptor 1 (TBLR1) was chosen as siRNA target. This is an important regulator of
HCC proliferation and tumor angiogenesis [116,117]. In different mice models of HCC (orthotropic and
xenograft models), this delivery system resulted in an active and specific interaction with hepatocytes
through the FA-targeting and demonstrated to be a safe approach, easily trackable with non-invasive
imaging tools [116].
The v3 and v5 integrins are overexpressed on the surface of the angiogenic endothelium of
different malignant tumors including HCC [118]. RGD-PEG-g-PEI-SPIONs delivery particles were
developed and loaded with an anti-Survivin siRNA [119]. In a subcutaneous mouse model of HCC,
RGD-PEG-g-PEI-SPIONs injected via the tail vein, efficiently and specifically inhibited tumor growth
promoting tumor cell apoptosis/necrosis. However, no significant effect on tumor angiogenesis was
observed. This leaves open the possibility that mechanisms, other than those predicted, might have
contributed to the effects of the RGD-PEG-g-PEI-SPIONs particles.
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Table 3. In vivo targeted delivery of siRNAs to HCC.
Delivery Material and
Particle Size
HCC Targeting
Antigen HCC Model
siRNA mRNA
Target Reference
Urocanic acid-modified
galactosylated trimethyl
chitosan (UA-GT)
170 nm
ASGP-R
QGY-7703 and mouse
xenograft subcutaneous
model (systemic delivery)
VEGF [114]
Galactose modified
trymethil
chitosan-cystein (GTC)
130–160 nm
ASGP-R xenograft mice model ofHCC (oral administration) Survivin and VEGF [108]
GTCs polyplexes with
distinct siRNA binding
affinity
135–170 nm
ASGP-R
QGY-7703 and xenograft
mice model of HCC
(intra-tumor injection)
VEGF [115]
FA-PEG-g-PEI-SPION
60 nm FR
orthotropic and xenograft
models (systemic delivery) TBLR1 [116]
RGD-PEG-g-PEI-SPION
122 nm
v3 and v5
integrins
Bel-7402 and mouse
xenograft subcutaneous
model (systemic delivery)
Survivin [119]
6. Conclusions
The works above reported clearly witness the efforts of the scientific community for the development
of siRNA delivery systems in general and for HCC in particular. Because of the effectiveness of action,
siRNAs have the potential to be used as bullets to hit the expression of disease-causing genes. However,
their intrinsic fragility makes their use as naked molecules impossible. Thus, it is necessary to develop
delivery systems able to confer protection and targeting HCC cells.
Among the different delivery materials so far tested, polymers represent a very attracting class of
materials. Because of their plasticity, biocompatibility and relative low costs, polymers are appealing
materials, which can be employed to generate sophisticated and smart delivery systems. It is now
clear that the delivery vector not only has to provide protection against siRNA degradation, but it
also needs to allow overcoming some key steps in the delivery process. In particular, it has to favor
accumulation in the tumor, targeting of tumor cells and then allow efficient siRNA release into the cell.
In the specific case of siRNA delivery to HCC, we believe the following aspects have to be
addressed. First, as the arterial supply in HCC increases with the progression of the disease, it may be
advisable to consider the arterial delivery route (TACE) in more advanced HCC forms and vein in
early HCC forms. Second, to favor the margination of the particles thus promoting the EPR effect and
liver accumulation, the particles diameter should be of about 1 m. Third, following extravasation,
particles may be able to undergo fragmentation originating nm particles. This size seems to be
appropriate for ECM crossing even if, as above discussed, this barrier may not be particularly difficult
to overcome in HCC. Fourth, targeting of HCC cells may be achieved equipping the delivery polymers
with specific antigen. Fifth, siRNA delivery should be triggered by the low pH, originated by the
biochemical pathways preferentially active in the tumor cell. At this step, the endosomal escape
property of the delivery material is also relevant. Sixth, the use of siRNA directed against specific HCC
oncogenes can further improve specificity and effectiveness. Finally, the possibility to mathematical
modelling the entire process can certainly contribute to optimize and speed up the development of
HCC delivery strategies.
From all the above considerations, it is clear that the solution of the problem is definitively not
easy and necessitates the fine-tuning of different variables. Only the synergistic action of different
competences spanning from physiology, molecular biology, biochemistry, medicine and engineering
can succeed in this task. Despite this, the many encouraging experimental works presented in this
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review can pave the way to the identification of novel and efficient delivery solutions for siRNA
to HCC.
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